Analysing the guidelines and assessment tools for Real-World Evidence studies
| dc.rights.license | CC-BY-NC-ND | |
| dc.contributor.advisor | Wang, J. | |
| dc.contributor.author | Hartog, Michiel | |
| dc.date.accessioned | 2023-12-31T02:01:44Z | |
| dc.date.available | 2023-12-31T02:01:44Z | |
| dc.date.issued | 2023 | |
| dc.identifier.uri | https://studenttheses.uu.nl/handle/20.500.12932/45698 | |
| dc.description.sponsorship | Utrecht University | |
| dc.language.iso | EN | |
| dc.subject | Non-randomised interventional studies, as a source of real-world data, provide valuable information for decision-makers around the world. As non-randomised studies are more susceptible to biases, their quality, in terms of risk of bias and reporting, should be evaluated, with the help of quality assessment tools. For this reason, health technology assessment (HTA) agencies rely on critical appraisal tools to evaluate non-randomised studies. | |
| dc.title | Analysing the guidelines and assessment tools for Real-World Evidence studies | |
| dc.type.content | Master Thesis | |
| dc.rights.accessrights | Open Access | |
| dc.subject.courseuu | Science and Business Management | |
| dc.thesis.id | 15985 |